By using the site you agree and are held Akebia Therapeutics (AKBA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). We, therefore, hold a negative evaluation of this stock. AKBA Stock Analysis - [Full Report] Free Signup: Advanced stock screener. All rights reserved. I’m not trying to trip you up or send you down the rabbit hole on a secret speculative stock. Never miss a profitable trade. If you’re anything like me, then Christmas always has a way of sneaking up on you. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.02. Macquarie Group Ltd. bought a new position in Akebia Therapeutics in the 2nd quarter valued at $60,000. Specifically, 8 analysts have assigned AKBA a recommendation rating as follows: 1 rate it as a Hold; 6 advise Buy while none analyst(s) assign an Outperform rating. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. Do Not Sell My Information. Akebia Therapeutics Inc. () Stock Market info Recommendations: Buy or sell Akebia Therapeutics stock? The AKBA stock forecast is provided by MarketClub with their Trade Triangle system. Private Advisor Group LLC bought a new stake in Akebia Therapeutics during the 2nd quarter worth approximately $25,000. During the last day, the stock moved $0.0900 between high and low, or 2.51%. Valeo Financial Advisors LLC now owns 8,245 shares of the biopharmaceutical company's stock valued at $112,000 after buying an additional 800 shares during the last quarter. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. featured in The Global Fintech Index 2020 as the top Fintech company of the country. Buy, Sell Or Hold Akebia Therapeutics, Inc. (NASDAQ:AKBA) At $2.73? 5 analysts, 1 (20%) are recommending AKBA as a Strong Buy, 3 (60%) are recommending AKBA as a Buy, 0 (0%) are recommending AKBA as a Hold, 0 (0%) are recommending AKBA as a Sell, and 1 (20%) are recommending AKBA as a Strong Sell. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Great West Life Assurance Co. Can boosted its position in Akebia Therapeutics by 66.3% in the 2nd quarter. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings. None analyst(s) have tagged the Akebia Therapeutics, Inc. (AKBA) stock as Underperform, with 1 recommending Sell. To see all exchange delays and terms of use please see disclaimer. Real-time data provided for free by IEX. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Akebia Therapeutics (AKBA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). After each calculation, the program assigns a buy, sell or hold value for each study, depending on where the price lies in reference to the common interpretation of the study. No stop-loss is set. We hold an negative evaluation for this stock. Should I buy or sell AKBA? Opinions of the stock are interesting as 5 analysts out of 7 who provided ratings for Akebia Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 1 as “sell.” View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Out of . They issued a "buy" rating and a $18.00 price target for the company. You can opt out at any time. On a fall, the stock will find some support from the short-term average at $3.50. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Top Penny Stocks To Buy [or sell] In October: Akebia Therapeutics Inc. First up on this list of penny stocks to watch is Akebia Therapeutics Inc. (AKBA Stock Report). We are all together in this COVID-19 pandemic. This is why we are offering FREE 14 days TRIAL SUBSCRIPTIONS with no further commitments. Learn more. Given the current short-term trend, the stock is expected to rise 27.47% during the next 3 months and, with a 90% probability hold a price between $4.35 and $7.03 at the end of this 3-month period. View IEX’s Terms of Use. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Akebia Therapeutics Inc (AKBA) stock is trading at $2.79 as of 9:44 AM on Friday, Sep 4, an increase of $0.13, or 5.09% from the previous closing price of $2.65. There are mixed signals in the stock today. HC Wainwright is very positive to AKBA and gave it a "Buy" rating on March 08, 2021. © American Consumer News, LLC dba MarketBeat® 2010-2021. WhatsApp. Furthermore, there is currently a sell signal from the 3 months Moving Average Convergence Divergence (MACD). Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell … The Akebia Therapeutics stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. Get daily stock ideas top-performing Wall Street analysts. Facebook. Jeff Brown just released a new research report. Eric Enderson - November 19, 2020. Institutional investors and hedge funds own 76.75% of the company's stock. AKBA has been the subject of several other research reports. Equities research analysts at Cantor Fitzgerald initiated coverage on shares of Akebia Therapeutics (NASDAQ:AKBA) in a research note issued to investors on Monday, The Fly reports. Twitter. Learn everything you need to know about successful options trading with this three-part video course. Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Free Signup: The predicted opening price is based on yesterday's movements between high, low, and the closing price. This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. Learn about financial terms, types of investments, trading strategies and more. And once you get to Christmas, it means that the end of the year is just a week away. Bitcoin broke through $40,000…. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements. If the lower trend floor at $3.41 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Price: $3.61 Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Use the Zacks Rank and Style Scores to find out is AKBA is right for your portfolio. As a group, equities research analysts forecast that Akebia Therapeutics will post -1.5 EPS for the current fiscal year. This story was reviewed by MarketBeat's editorial team prior to publication. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The Akebia Therapeutics stock price fell by -2.96% on the last day (Friday, 12th Mar 2021) from $3.72 to $3.61. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day! All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Export data to Excel for your own analysis. Receive a free world-class investing education from MarketBeat. JPMorgan Chase & Co. cut Akebia Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Thursday, September 3rd. Akebia Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. Akebia Therapeutics (NASDAQ:AKBA) was downgraded by investment analysts at BidaskClub from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Wednesday, BidAskClub reports. Should I buy Akebia Therapeutics, Inc. (AKBA)? I’m looking at buying into companies that appear to be good buys as the economy recovers. Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. View Akebia Therapeutics, Inc. AKBA investment & stock information. 7 analysts offering their recommendations for the stock have an average rating of 2.20, where 2 rate it as a Hold and 0 think it is a “Overweight”. Identify stocks that meet your criteria using seven unique stock screeners. Get a free AKBA technical analysis report to make a better AKBA stock predictions on how the stock will perform in the near future. AKBA's rank also includes a fundamental score of 79. The Akebia Therapeutics stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.This signal is rare and, in most cases, gives substantial returns. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. The price target was set to $9.00 → $6.00. All users should speak with their financial advisor before buying or selling any securities. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Akebia Therapeutics (NASDAQ:AKBA) was downgraded by investment analysts at BidaskClub from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Wednesday, BidAskClub reports. The stock has a consensus analyst rating of "Hold." Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. Looking for new stock ideas? So shareholders might well want to know whether insiders have been buying or selling shares in Akebia Therapeutics, Inc. (NASDAQ:AKBA). The company that develops and commercializes renal therapeutics for patients who have kidney diseases. This company can help you start investing in this highly valuable asset class. Pinterest. AKBA Stock Forecast - Is AKBA a buy or sell? Please send any questions or comments about this story to [email protected]. About the Akebia Therapeutics, Inc. stock forecast. ... and a bulleted list of reasons to buy or sell the stock. Your losses are our losses too. And that’s what I’m trying to do in this special presentation. AKBA on StockCharts.com ETFs Holding AKBA Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. On the last day, the trading volume fell by -570 thousand shares and in total, 3 million shares were bought and sold for approximately $12.35 million. The past year's Accounts Payable Turnover was at 7.31. Akebia Therapeutics Inc stock has fallen -24.49% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives AKBA stock a score of 73 out of a possible 100.. That rank is influenced by a short-term technical score of 80. Akebia Therapeutics (NASDAQ:AKBA) last posted its quarterly earnings data on Monday, August 10th.